Reportlinker Adds Analytical Tool - Hematological Cancers

NEW YORK, Aug. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Analytical Tool - Hematological Cancers

http://www.reportlinker.com/p0284899/Analytical-Tool---Hematological-Cancers.html

"Analytical Tool – Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are three products already appreciated by many of our customers:

Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking

Lymphoma Drug Development Strategies at Work - Define Your Competition

Hematological Cancers Drug Pipeline Update 2010*

The Package Includes:

- A progress analysis on current and emerging drugs

- Information on most companies active in R&D

- Information on key industry related projects

- Data from most important clinical trials

- Information on early developmental stage projects

- Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:

- Tracking cutting edge companies, therapies and new technologies

- Rapid identification of partners & competitors

- Laying down a comprehensive framework for further analysis of the field

- Producing presentations surrounding the development of leukemia therapeutics

- Identifying emerging products & key areas of pharmaceutical R&D

*BioSeeker's CD-ROM searchable database reflects the most recent advances in the field of hematological cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker Group CD-ROM searchable databases is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker Group's CD-ROM searchable databases give better overview and specific search capabilities.

To order this report:

Biotechnology Industry: Analytical Tool - Hematological Cancers

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker

Suggested Articles

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.